The FSUE Moscow Endocrine Plant carries out measures to modernize the design of primary and secondary packaging of drugs for medical use. The new packaging will increase the recognition of own drugs manufactured by the FSUE Moscow Endocrine Plant, it is more attractive to consumers, has characteristic distinguishing features.
Replacement of the packaging is planned in relation to the full line of its drugs drugs produced by the Enterprise. The transition to new cardboard packs will be carried out gradually throughout 2017 as products are sold in their previous packaging.
To date the transition to a new packaging has been made for the drug Rimantadine 50 mg tablets, starting from the 790916 series in 2016, as well as for a number of drugs intended for use in the hospital sector.
Thus, in pharmacies both drugs in new consumer packaging and drugs in previous packaging can be purchased.
Information on changes in the packaging of drugs with the image of new cardboard packs will be posted on the official website of the Enterprise in the "Products" section as it switches to a new primary and secondary packaging.
In addition to its own drugs manufactured by the FSUE Moscow Endocrine Plant, the consumer packaging of the drug Emoxipin 1% eye drops has been updated, starting from the 180216 series in 2016, the Federal Service for Supervision of Healthcare published a corresponding information letter No. 02 I-1739/16 from 07.09.2016, which is posted on the electronic resource of Roszdravnadzor.
Comment type is not specified in the component properties.